ArticleLipids in health and disease2025
The association between dyslipidemia and intervertebral disc degeneration: a prospective cohort study based on the UK biobank.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering the regulatory mechanism and therapeutic potential of ECM degradation in intervertebral disc degeneration via multi-omics integration.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIntervertebral disc degeneration (IDD) is a progressive and debilitating condition associated with aging, inflammation, and metabolic disorders. Although dyslipidemia has been implicated in IDD pathogenesis, large-scale prospective evidence remains limited. This study aimed to investigate the observational association between serum lipid traits and IDD risk using data from the UK Biobank.
methodsA prospective cohort study was conducted among 298,226 participants (aged 37-73 years; 54.2% female, n = 161,770) without IDD at baseline. Serum lipid levels, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A (Apo A) and apolipoprotein B (Apo B), were measured at enrollment. IDD cases were identified via ICD-10 codes. Cox proportional hazards models, adjusted for demographic, lifestyle, and comorbid factors, were used to assess associations between lipid levels and IDD risk. Restricted cubic spline analyses explored potential nonlinear relationships, and subgroup analyses examined effect modifications.
resultsOver a median follow-up of 12 years, 8,745 participants developed IDD. Higher levels of TC (> 5.64 mmol/L) and TG (> 1.51 mmol/L) were significantly associated with increased IDD risk. Compared with the lowest quintile, the highest TC quintile was associated with a 10.2% increased risk (HR = 1.102; 95% CI: 1.029-1.181; P = 0.006), and the highest TG quintile with an 11.3% increased risk (HR = 1.113; 95% CI: 1.036-1.195; P = 0.003), after full adjustment. No significant associations were found for LDL-C, HDL-C, Apo A, or Apo B after multivariable adjustment (all P > 0.05). Subgroup analyses revealed significant interactions between age and TG (P for interaction < 0.05), with younger participants (≤ 60 years) showing a stronger association. Additionally, age modified the effects of HDL-C and Apo A. These findings provide observational evidence that lipid traits may be differentially associated with IDD risk across age groups.
conclusionsHigher TC and TG levels were associated with increased IDD risk. These findings provide observational evidence for the role of lipid levels in stratifying IDD risk. Routine lipid screening may help identify high-risk individuals and guide early prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.